Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Cowen Health Care Conference Transcript

Mar 12, 2019 / 02:40PM GMT
Release Date Price: $90.14
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD and Senior Research Analyst

(technical difficulty)

give presentation in this room. It'll be probably partial amount of the time, we'll also do a bit of a fireside chat when J.J. is done with his prepared remarks. In the back, we also have CFO, Dan Spiegelman; and Traci McCarty of Investor Relations. J.J.?

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Thank you, Phil. Good morning, everybody. Pleasure to be here. This presentation will contain forward-looking statements, so please refer to our SEC filings.

So BioMarin is a 21-year old company. We now have 7 approved products in the market. We anticipate that they will be generating around $2 billion of revenue next year. And we -- in addition to the products on the market, we have a significant pipeline of products: vosoritide for achondroplasia; valrox for hemophilia A gene therapy; tralesinidase alfa for MPS IIIB. We anticipate filing an IND for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot